-
08 Apr
Talem Therapeutics has advanced development of candidate panel TATX-112, against an undisclosed target, into formal lead candidate characterization.
... READ MORE -
28 Mar
23-H7 binds to all tested variants of concern and blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action
... READ MORE -
-
16 Mar
The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy
... READ MORE -
-
19 Feb
Treatment of Syrian hamsters with a cocktail of four monoclonal antibodies resulted in strong anti-viral effects against SARS-CoV-2
... READ MORE